On 7 February, "#100tífiques" returned for its sixth edition, a macro-event that has become a benchmark for advocacy within the Catalan female research community and schools. Expanding on last year's participant numbers, thirteen scientists from IGTP took part in this event.
At the IGTP TODAY
A newly developed therapeutic strategy offers potential in treating neurofibromatosis type 1 skin tumours
Researchers from IGTP have made progress exploring potential treatments for skin tumours associated with neurofibromatosis type 1. Their findings in cell models have been published in the journal JCI Insight.
A research team, led by Dr. Conxi Lázaro, from IDIBELL and ICO, and Dr. Eduard Serra, from IGTP, has published in the journal Molecular Oncology the expansion of a precision medicine platform to analyse and improve treatments for malignant peripheral nerve sheath tumours.
The four visits under the "Visita la recerca" (Visit the research) cycle of the Fundació La Marató de TV3 at the Germans Trias i Pujol Research Institute (IGTP) have drawn to a successful close. More than 50 collaborators have had the opportunity to gain insight into various research projects funded through this charitable initiative.
Comprehensive genomic characterisation of malignant peripheral nerve tumour-derived lines challenges current diagnostic criteria
The Hereditary Cancer research group from the Germans Trias i Pujol Research Institute (IGTP) has led an international collaboration that has allowed the genomic characterisation of the most commonly used cell lines derived from malignant peripheral nerve sheath tumours (MPNSTs). This research has generated a detailed catalogue of genomic alterations for each cell line, which can be used to develop strategies for precision therapies. At the same time, a genomic repository has been created that is open to all researchers interested in these tumours. The work has been published in the journal iScience.
CARE, the Translational Program in Cancer Research is the first transversal program promoted by the Germans Trias i Pujol Research Institute (IGTP), and it aims to become a bridge for researchers in the field of cancer who want to bring basic and clinical research together, so that the knowledge and the tools generated in the laboratory can benefit the patient.
The Hereditary Cancer Group have published a study in Cell Reports in which they describe the generation of a model system based on induced pluripotent stem cells (iPSCs) that is able to generate human neurofibromas in mice. These tumours arise in people with the genetic disease Neurofibromatosis Type 1, a prevalent condition occurring in one in every 3,000 people. To date, a robust method for generating human neurofibromas in mice has been lacking, and the model developed opens up the possibility of testing new treatments for these tumours.
The Germans Trias i Pujol Research Institute (IGTP) has received a total of 305,680 euros for three projects on rare diseases in which it participates or coordinates. In total the three projects have received financing of more than a million euros, to be divided between the several institutions participating. This edition of the fundraising marathon will fund a total of 41 biomedical research projects of excellence on rare diseases. The projects aim to provide better diagnosis at birth and provide more efficient and safer treatments to improve quality of life and extend the lifespans of people affected.
This years' edition of the Workshop on Rare Diseases took place at the IGTP this Thursday with the title 'A Multidisciplinary Approach to Rare Diseases' timed for the International Day for Rare Diseases, celebrated this year on 29 February. The key to improving the management of this type of disease is dialogue between different specialty areas and a much more global approach. This must be coupled with the inclusion of research staff when deciding on the lines of research to be advanced.
Last Friday the first update meeting at national level to take a global view of the healthcare situation and present the latest research data for Neurofibromatosis type 2 (NF2) took place at the IGTP. This pioneering event was organized by the members of the National Reference Centre in genetic neuro-cutaneous syndromes (Facomatosis), (CSUR) on the Can Ruti Campus and also included patients and families affected by the disease.